Autologous Ex Vivo Lentiviral Gene Therapy for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (2019)
Attributed to:
Phase I/II trial of lentiviral vector mediated gene therapy for Adenosine Deaminase deficiency
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Conference/Paper/Proceeding/Abstract
Volume: 39
Parent Publication: JOURNAL OF CLINICAL IMMUNOLOGY
ISSN: 0271-9142